NCT07074821

Brief Summary

Tunneled hemodialysis catheters are susceptible to infection with high incidence of complication to the hemodialysis patients .The study aimed to prevent catheter infection through comparing use of antimicrobial solution (Taurolidine) when used as lock solution installed in the lumen of the catheter at the end of the hemodialysis session with the usually used lock solution heparin. The Study was performed on 100 hemodialysis patients over one year in Sohar hospital ,Oman .

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Mar 2023

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2023

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 29, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 24, 2024

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

May 4, 2025

Completed
3 months until next milestone

First Posted

Study publicly available on registry

July 20, 2025

Completed
Last Updated

July 20, 2025

Status Verified

July 1, 2025

Enrollment Period

1 year

First QC Date

May 4, 2025

Last Update Submit

July 18, 2025

Conditions

Keywords

catheter related infectionhemodialysisTaurolidine

Outcome Measures

Primary Outcomes (1)

  • Comparison between both groups in terms of incidence of Catheter related blood stream infection

    The investigators have studied the incidence of catheter related bacterial infection in both groups to determine superior effectiveness of Taurolidine lock solution than Heparin lock only in terms of prevention of infection .

    one year

Secondary Outcomes (1)

  • Comparison between both groups in terms of treatment cost

    one year

Study Arms (2)

Group (A) patients used usual Heparin used as tunneled hemodialysis lock solution

NO INTERVENTION

Measure incidence of catheter related blood stream infection while patients use Heparin as catheter lock

Group (B) patients used Taurolidine based lock solution as tunneled hemodialysis catheter lock

EXPERIMENTAL

Measure incidence of catheter related blood stream infection while patients use Taurolidine based lock solution as catheter lock

Drug: Taurolidine citrate 4% and heparin 500

Interventions

Taurolidine ,citrate 4% and heparin 500 units per ml used as lock solution in tunneled hemodialysis catheter

Group (B) patients used Taurolidine based lock solution as tunneled hemodialysis catheter lock

Eligibility Criteria

Age13 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • \- All clinically stable adult end stage renal disease patients commence regular hemodialysis through tunneled hemodialysis catheter at Sohar hospital hemodialysis unit.

You may not qualify if:

  • Patients with difficult vascular access and the tunneled hemodialysis catheter is the only functioning vascular access .
  • Patients with poor flow from the catheter.
  • Patients with active infection .
  • Patients have displayed allergic reactions to either citrate or taurolidine.
  • Patients were taking medication incompatible with either citrate or taurolidine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohar hospital

Sohar, Sohar, 00968, Oman

Location

MeSH Terms

Conditions

Catheter-Related Infections

Condition Hierarchy (Ancestors)

Infections

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

May 4, 2025

First Posted

July 20, 2025

Study Start

March 1, 2023

Primary Completion

February 29, 2024

Study Completion

July 24, 2024

Last Updated

July 20, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will share

Methodology and results

Locations